Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

John Harrington | Sep 5, 2017 at 12:59 PM EDT

Deaths Linked to Drug Overdoses Surge in US

Drug overdose deaths for the 12 months ending January 2017 rose 21%, according to data from the CDC. Maryland led…

Chris Lange | Sep 5, 2017 at 11:40 AM EDT

FDA Crushes Cellectis With Clinical Hold

Cellectis shares tumbled early on Tuesday after the firm announced that a couple of its early-stage studies were put on…

Chris Lange | Sep 5, 2017 at 10:35 AM EDT

BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win

BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its…

Chris Lange | Sep 5, 2017 at 9:50 AM EDT

Insmed More Than Doubles on Late-Stage Trial

Insmed saw its shares more than double early on Tuesday after the firm released late-stage results from its clinical study…

Chris Lange | Aug 31, 2017 at 10:20 AM EDT

FDA Crushes SteadyMed With Refusal to File Letter

SteadyMed shares plummeted after the firm had a setback from the FDA regarding its pulmonary arterial hypertension treatment.

Paul Ausick | Aug 30, 2017 at 2:05 PM EDT

1.5 Million Americans a Year Make Medication Errors

Taking more than a prescribed amount of medication leads to nearly 1.5 million calls annually to U.S. poison control centers.

Trey Thoelcke | Aug 30, 2017 at 1:05 PM EDT

ImmunoGen Riding High on Jazz Pharma Deal

ImmunoGen announced this week that it has decided to partner with Jazz Pharmaceuticals, and investors have pushed Immunogen shares to…

Chris Lange | Aug 30, 2017 at 10:10 AM EDT

Mazor Robotics Jumps After Medtronic Collaboration Update

Mazor Robotics saw its shares make a handy gain to kick off hump day after it was announced that the…

Chris Lange | Aug 30, 2017 at 8:40 AM EDT

Why Otonomy Shares Are Getting Absolutely Crushed

Otonomy saw its shares crater after the firm announced results for its Averts-1 late-stage trial of Otividex in patients with…

Chris Lange | Aug 29, 2017 at 10:10 AM EDT

ImmunoGen and Jazz Enter Into Global Collaboration

ImmunoGen has decided to partner with Jazz Pharmaceuticals for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate programs.

Chris Lange | Aug 29, 2017 at 9:50 AM EDT

Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter

Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from…

Chris Lange | Aug 28, 2017 at 10:00 AM EDT

Gilead Moves to Acquire Kite Pharma

Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to…

Chris Lange | Aug 25, 2017 at 10:10 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Aug 25, 2017 at 9:55 AM EDT

Short Sellers Run for Cover From Major Pharma

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 23, 2017 at 12:50 PM EDT

How the Ultragenyx Hype Went From a Very Promising to a 52-Week Low

Ultragenyx Pharmaceutical just hit a 52-week low and analysts have slashed and burned their price target expectations. This is after…

1 … 157 158 159 160 161 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Deaths Linked to Drug Overdoses Surge in US

FDA Crushes Cellectis With Clinical Hold

BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win

Insmed More Than Doubles on Late-Stage Trial

FDA Crushes SteadyMed With Refusal to File Letter

1.5 Million Americans a Year Make Medication Errors

ImmunoGen Riding High on Jazz Pharma Deal

Mazor Robotics Jumps After Medtronic Collaboration Update

Why Otonomy Shares Are Getting Absolutely Crushed

ImmunoGen and Jazz Enter Into Global Collaboration

Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter

Gilead Moves to Acquire Kite Pharma

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Run for Cover From Major Pharma

How the Ultragenyx Hype Went From a Very Promising to a 52-Week Low

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

Health and Healthcare Articles

All Health and Healthcare Articles

Deaths Linked to Drug Overdoses Surge in US

FDA Crushes Cellectis With Clinical Hold

BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win

Insmed More Than Doubles on Late-Stage Trial

FDA Crushes SteadyMed With Refusal to File Letter

1.5 Million Americans a Year Make Medication Errors

ImmunoGen Riding High on Jazz Pharma Deal

Mazor Robotics Jumps After Medtronic Collaboration Update

Why Otonomy Shares Are Getting Absolutely Crushed

ImmunoGen and Jazz Enter Into Global Collaboration

Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter

Gilead Moves to Acquire Kite Pharma

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Run for Cover From Major Pharma

How the Ultragenyx Hype Went From a Very Promising to a 52-Week Low

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

Featured Reads

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market